Comparative Pharmacology
Head-to-head clinical analysis: CLONAZEPAM versus MENRIUM 5 2.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLONAZEPAM versus MENRIUM 5 2.
CLONAZEPAM vs MENRIUM 5-2
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enhances GABA-A receptor inhibitory neurotransmission by binding to benzodiazepine binding site, increasing frequency of chloride channel opening, leading to neuronal hyperpolarization.
Combination of chlordiazepoxide (benzodiazepine) potentiating GABA-A receptor activity, and clidinium (antimuscarinic) blocking muscarinic acetylcholine receptors.
0.5 mg orally three times daily; maximum 20 mg/day
1 tablet orally every 6-8 hours as needed for anxiety, up to 4 tablets per day. Each tablet contains chlordiazepoxide 5 mg and clidinium bromide 2.5 mg.
None Documented
None Documented
Terminal elimination half-life: 19-60 hours (mean 30-40 hours); clinical context: long-acting benzodiazepine, allows once or twice daily dosing; accumulation occurs with repeated use.
Clinical Note
moderateClonazepam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Clonazepam."
Clinical Note
moderateClonazepam + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Clonazepam."
Clinical Note
moderateClonazepam + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Clonazepam."
Clinical Note
moderateClonazepam + Fluconazole
Chlordiazepoxide: 5-30 hours (increases with age, hepatic impairment); Clidinium: 8-12 hours
Renal: 50-70% as metabolites (mostly glucuronide conjugates), <2% unchanged; fecal: 10-20%; biliary: minor.
Chlordiazepoxide: 90-96% renal as metabolites, <5% unchanged; Clidinium: 70-80% fecal, 10-20% renal as metabolites
Category D/X
Category C
Benzodiazepine
Benzodiazepine/Estrogen Combination
"The metabolism of Fluconazole can be decreased when combined with Clonazepam."